Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease

被引:19
|
作者
Lang, Sonja [1 ,2 ]
Martin, Anna [1 ]
Zhang, Xinlian [3 ]
Farowski, Fedja [4 ,5 ,6 ]
Wisplinghoff, Hilmar [7 ,8 ,9 ]
J. G. T. Vehreschild, Maria [4 ,5 ,6 ]
Krawczyk, Marcin [10 ,11 ]
Nowag, Angela [7 ,9 ]
Kretzschmar, Anne [7 ]
Scholz, Claus [7 ]
Kasper, Philipp [1 ]
Roderburg, Christoph [12 ]
Mohr, Raphael [13 ,14 ]
Lammert, Frank [10 ,15 ]
Tacke, Frank [13 ,14 ]
Schnabl, Bernd [2 ,16 ]
Goeser, Tobias [1 ]
Steffen, Hans-Michael [1 ]
Demir, Muenevver [13 ,14 ]
机构
[1] Univ Cologne, Univ Hosp Cologne, Dept Gastroenterol & Hepatol, Fac Med, Cologne, Germany
[2] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Herbert Wertheim Sch Publ Hlth & Human Longev Sci, Div Biostat & Bioinformat, La Jolla, CA 92093 USA
[4] Univ Cologne, Dept Internal Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseld, Cologne, Germany
[5] German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany
[6] Goethe Univ Frankfurt, Dept Internal Med, Infect Dis, Frankfurt, Germany
[7] Wisplinghoff Labs, Cologne, Germany
[8] Univ Witten Herdecke, Inst Virol & Med Microbiol, Witten, Germany
[9] Univ Cologne, Univ Hosp Cologne, Inst Med Microbiol Immunol & Hyg, Fac Med, Cologne, Germany
[10] Saarland Univ, Med Ctr, Dept Med 2, Homburg, Germany
[11] Med Univ Warsaw, Dept Gen Transplant & Liver Surg, Lab Metab Liver Dis, Warsaw, Poland
[12] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Med Fac, Clin Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany
[13] Charite, Campus Virchow Clin, Dept Hepatol & Gastroenterol, Berlin, Germany
[14] Campus Charite Mitte, Berlin, Germany
[15] Hannover Med Sch MHH, Hannover, Germany
[16] VA San Diego Healthcare Syst, Dept Med, San Diego, CA USA
关键词
microbiome; microbiota; NAFLD; NASH; nutrition; PNPLA3; REPORTED ENERGY-INTAKE; FIBROSIS; ACTIVATION; DYSBIOSIS; SEVERITY; RS738409; OUTCOMES; NAFLD; RISK;
D O I
10.1111/liv.14899
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims Non-alcoholic fatty liver disease (NAFLD) is a global health burden. Risk factors for disease severity include older age, increased body mass index (BMI), diabetes, genetic variants, dietary factors and gut microbiota alterations. However, the interdependence of these factors and their individual impact on disease severity remain unknown. Methods In this cross-sectional study, we performed 16S gene sequencing using fecal samples, collected dietary intake, PNPLA3 gene variants and clinical and liver histology parameters in a well-described cohort of 180 NAFLD patients. Principal component analyses were used for dimensionality reduction of dietary and microbiota data. Simple and multiple stepwise ordinal regression analyses were performed. Results Complete data were available for 57 NAFLD patients. In the simple regression analysis, features associated with the metabolic syndrome had the highest importance regarding liver disease severity. In the multiple regression analysis, BMI was the most important factor associated with the fibrosis stage (OR per kg/m(2): 1.23, 95% CI 1.10-1.37, P < .001). The PNPLA3 risk allele had the strongest association with the histological grade of steatosis (OR 5.32, 95% CI 1.56-18.11, P = .007), followed by specific dietary patterns. Low abundances of Faecalibacterium, Bacteroides and Prevotella and high abundances of Gemmiger were associated with the degree of inflammation, ballooning and stages of fibrosis, even after taking other cofactors into account. Conclusions BMI had the strongest association with histological fibrosis, but PNPLA3 gene variants, gut bacterial features and dietary factors were all associated with different histology features, which underscore the multifactorial pathogenesis of NAFLD.
引用
收藏
页码:1576 / 1591
页数:16
相关论文
共 50 条
  • [31] PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-alcoholic Fatty Liver Disease
    Petta, Salvatore
    Valenti, Luca
    Marchesini, Giulio
    Di Marco, Vito
    Licata, Anna
    Camma, Calogero
    Barcellona, Maria Rosa
    Cabibi, Daniela
    Donati, Benedetta
    Fracanzani, Anna Ludovica
    Grimaudo, Stefania
    Parrinello, Gaspare
    Pipitone, Rosaria Maria
    Torres, Daniele
    Fargion, Silvia
    Licata, Giuseppe
    Craxi, Antonio
    HEPATOLOGY, 2013, 58 : 506A - 506A
  • [32] PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease
    Petta, Salvatore
    Valenti, Luca
    Marchesini, Giulio
    Di Marco, Vito
    Licata, Anna
    Camma, Calogero
    Barcellona, Maria Rosa
    Cabibi, Daniela
    Donati, Benedetta
    Fracanzani, Anna
    Grimaudo, Stefania
    Parrinello, Gaspare
    Pipitone, Rosaria Maria
    Torres, Daniele
    Fargion, Silvia
    Licata, Giuseppe
    Craxi, Antonio
    PLOS ONE, 2013, 8 (09):
  • [33] PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum
    Salameh, Habeeb
    Al Hanayneh, Muhannad
    Masadeh, Maen
    Naseemuddin, Mohammed
    Matin, Tasnia
    Erwin, Angelika
    Singal, Ashwani K.
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2016, 4 (03) : 175 - 191
  • [34] Role of Nutrition, Gene Polymorphism, and Gut Microbiota in Non-alcoholic Fatty Liver Disease
    Kong, Lingbo
    Lu, Yu
    Zhang, Siyu
    Nan, Yuemin
    Qiao, Liang
    DISCOVERY MEDICINE, 2017, 24 (131) : 95 - 106
  • [35] APOC3 and PNPLA3 in non-alcoholic fatty liver disease: Need to clear the air
    Duseja, Ajay
    Aggarwal, Rakesh
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (05) : 848 - 851
  • [36] Association of the serum uric acid level with liver histology in biopsy-proven non-alcoholic fatty liver disease
    Huang, Qian
    Yu, Jianhua
    Zhang, Xiantu
    Liu, Shourong
    Ge, Yanyan
    BIOMEDICAL REPORTS, 2016, 5 (02) : 188 - 192
  • [37] Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration
    Patel, Y. A.
    Gifford, E. J.
    Glass, L. M.
    McNeil, R.
    Turner, M. J.
    Han, B.
    Provenzale, D.
    Choi, S. S.
    Moylan, C. A.
    Hunt, C. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (02) : 268 - 278
  • [38] Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease
    Seko, Yuya
    Sumida, Yoshio
    Tanaka, Saiyu
    Taketani, Hiroyoshi
    Kanemasa, Kazuyuki
    Ishiba, Hiroshi
    Okajima, Akira
    Nishimura, Takeshi
    Yamaguchi, Kanji
    Moriguchi, Michihisa
    Mitsuyoshi, Hironori
    Yasui, Kohichiroh
    Minami, Masahito
    Itoh, Yoshito
    HEPATOLOGY RESEARCH, 2015, 45 (07) : 728 - 738
  • [39] Prevalence and Treatment of Arterial Hypertension Among Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease
    Schramm, C.
    Dinter, J.
    Demir, M.
    Lengerli, K.
    Toex, U.
    Steffen, H-M.
    JOURNAL FUR HYPERTONIE, 2010, 14 (04): : 21 - 25
  • [40] Risk factors associated with subclinical atherosclerosis in the patients with biopsy-proven non-alcoholic fatty liver disease
    Arai, Taeang
    Atsukawa, Masanori
    Tsubota, Akihito
    Yoshida, Yuji
    Okubo, Tomomi
    Hayama, Korenobu
    Nakagawa, Ai
    Itokawa, Norio
    Kondo, Chisa
    Iio, Etsuko
    Tanaka, Yasuhito
    Iwakiri, Katsuhiko
    JOURNAL OF HEPATOLOGY, 2020, 73 : S168 - S169